Sage Group News

The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT® 7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe 7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK (December 20, 2018) – Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately

Opportunity to Partner OncoSec: a Novel Immunotherapy Company

10 December 2018 - New York and London - The Sage Group is pleased to announce that it is working with OncoSec, an American corporation, to identify one of more strategic global partners for its TAVO technology. TAVO is an exciting approach to treatment of solid tumors such as melanoma and Triple Negative Breast Cancer using a powerful new approach to immunooncology-based thearapeutics. • A late stage oncology company with clinical data in five different indications. • Demonstrated better than a 30 percent response rates in melanoma, both as monotherapy and in combination with checkpoint therapy. • Evidence for abscopal effects reflected in intratumoral treatment having whole body benefits.